Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 801–900 of 1,000
Bonelli, R. M., & Beal, M. F. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00030-9 · Cited by 20
Animal models of Kennedy disease
Merry, D. E. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.471 · Cited by 19
Tip60 HAT Action Mediates Environmental Enrichment Induced Cognitive Restoration
Xu, S., Panikker, P., Iqbal, S., & Elefant, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159623 · Cited by 20
Amyotrophic Lateral Sclerosis: From Disease Mechanisms to Therapies
Bruijn, L. I. (2002) · BioTechniques · doi:10.2144/02325dd01 · Cited by 17
Development of novel therapies for Huntington's disease: hope and challenge1
Qin, Z., Wang, J., & Gu, Z. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00520.x · Cited by 20
Hwang, Y. J., Hyeon, S. J., Kim, Y., Lim, S., Lee, M. Y., Kim, J., Londhe, A. M., Gotina, L., Kim, Y., Pae, A. N., et al. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1900160 · Cited by 18
Xu, S., Li, G., Ye, X., Chen, D., Chen, Z., Xu, Z., Daniele, M., Tambone, S., Ceccacci, A., Tomei, L., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010302 · Cited by 22
“We first tested flies with neuronal expression of human HTT exon1 carrying 93 glutamines (HTTex1-93Q), a well-established HD model that manifests robust neuronal degeneration in targeted neurons [51].”
Shaw, J. L., Zhang, S., & Chang, K. T. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1163-15.2015 · Cited by 15
“…successfully as a model system to investigate mechanisms underlying various neurological disorders (Warrick et al., 1998; Feany and Bender, 2000; Steffan et al., 2001; Jackson et al., 2002; Chen et al., 2003; Yang et al., 2003; Iijima et al., 2004; Clark et al., 2006; Carmine-Simmen et al.,…”
BackgroundPathogenesis‐targeting therapeutics for spinal and bulbar muscular atrophy (SBMA)
Suzuki, K., Kastuno, M., Banno, H., & Sobue, G. (2009) · Neuropathology · doi:10.1111/j.1440-1789.2009.01013.x · Cited by 17
“quent restoration of gene transcription, HDAC inhibitors have been considered to be of therapeutic benefit in polyglutamine diseases.(50,51) Butyrate is the first HDAC inhibitor to be discovered, and the related compound, phenylbutyrate, has been successfully employed in experimental cancer therapy.”
BackgroundAge-associated chromatin relaxation is enhanced in Huntington’s disease mice
Park, M., Min, B., Jeon, K., Cho, S., Park, J. S., Kim, J., Jeon, J., Song, J., Kim, S., Jeong, S., et al. (2017) · Aging · doi:10.18632/aging.101193 · Cited by 14
“…is more enhanced in HD than in wt mouse. mHTT expression leads to reduced histone acetylation through its association with histone acetyltransferases, including CBP and P300/CBP-associated factor [17, 54], or aggregating CBP and other transcriptional regulators in the nucleus and cytoplasm [55].”
InfluentialSingh, V. P., Sharma, R. K., Athilingam, T., Sinha, P., Sinha, N., & Thakur, A. K. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00491 · Cited by 15
Taniguchi, H., & Moore, A. W. (2014) · BioEssays · doi:10.1002/bies.201400087 · Cited by 20
Modeling Age‐Related Diseases in Drosophila: Can this Fly?
Michno, K., van de Hoef, D. L., Wu, H., & Boulianne, G. L. (2005) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)71006-1 · Cited by 19
Opposite effects of CBP and p300 in glucocorticoid signaling in astrocytes
Fonte, C., Trousson, A., Grenier, J., Schumacher, M., & Massaad, C. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.03.034 · Cited by 19
Gene Regulation in Neuronal Degeneration - Role of mSin3 and YY1 factors
Korhonen, P. (2002) · Cited by 18
Bypassing mitochondrial defects rescues Huntington's phenotypes in Drosophila
Campesan, S., Popolo, I. D., Marcou, K., Straatman-Iwanowska, A. A., Repici, M., Boytcheva, K. V., Cotton, V. E., Allcock, N., Rosato, E., Kyriacou, C. P., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106236 · Cited by 17
Signal transduction mechanisms in memory disorders
Shalin, S. C., Egli, R. E., Birnbaum, S. G., Roth, T. L., Levenson, J. M., & Sweatt, J. D. (2006) · Progress in brain research · doi:10.1016/s0079-6123(06)57003-7 · Cited by 14
Genome wide gene expression regulation by HIP1 Protein Interactor, HIPPI: Prediction and validation
Datta, M., Choudhury, A., Lahiri, A., & Bhattacharyya, N. P. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-463 · Cited by 16
“The altered genes were further analyzed to see whether any other transcription factor binding sites, particularly those TFs that are already known to be involved in HD, were enriched in their upstream promoters [19-24].”
BackgroundChongtham, A., Bornemann, D. J., Barbaro, B. A., Lukácsovich, T., Agrawal, N., Syed, A., Worthge, S. A., Purcell, J. M., Burke, J., Chin, T. M., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa001 · Cited by 14
Self-citationAssessing the cognitive status of Drosophila by the value-based feeding decision
Yu, C.-C., Chang, F.-C., Hong, Y.-H., Li, J., Chen, P., Chen, C., Chiu, T.-W., Lu, T., Wang, Y., & Kao, C.-F. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-021-00075-6 · Cited by 15
UsingDrosophilamodels of neurodegenerative diseases for drug discovery
Newman, T. A., Sinadinos, C., Johnston, A. H., Sealey, M. A., & Mudher, A. K. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.549124 · Cited by 18
“1 Candidate drug delivery to ameliorate disease protein-mediated neuronal dysfunction Of the many suspected pathogenic effects of expanded polyQ htt protein, transcriptional deregulation is believed to play a key role in HD (reviewed in [29]).”
BackgroundInfluentialEpigenetic Regulation of Longevity in Insects
Kozeretska, I. A., Serga, S. V., Koliada, A. K., & Vaiserman, A. M. (2017) · Advances in insect physiology · doi:10.1016/bs.aiip.2017.03.001 · Cited by 15
Yeh, P.-A., Liu, Y., Chu, W.-C., Liu, J., & Sun, Y. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy160 · Cited by 16
Reactivation of silenced genes and transcriptional therapy
Chiurazzi, P., & Neri, G. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072838 · Cited by 16
“Steffan et al. (2001) went on to demonstrate that the HDAC inhibitors sodium butyrate and suberoylanilide hydroxamic acid (SAHA) can restore wild-type levels of acetylated histones H3 and H4 in cell culture and can arrest ongoing progressive neuronal degenera- 62 Cytogenet Genome Res 100:56–64…”
BackgroundYin, Y., Ma, P., Wang, S., Zhang, Y., Han, R., Huo, C., Wu, M., & Deng, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05122-y · Cited by 18
“Drosophila food intake measurement Food intake was measured by the capillary feeder assay (CAFÉ) with modifications [77].”
BackgroundInfluentialOnkar, A., Deepashree, S., Rai, A., Gupta, A., Gupta, N., & Ganesh, S. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050238 · Cited by 15
“An equal amount of total tissue protein was analyzed using 8% SDS-PAGE and processed for standard immunoblotting protocol (Steffan et al., 2001).”
Delfino, L., Mason, R. P., Kyriacou, C. P., Giorgini, F., & Rosato, E. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-200411 · Cited by 15
“We used an X-linked elav-GAL4 driver to express a mutant HTT exon 1 fragment containing a stretch of 93 glutamines (HTT93Q) in all neuronal cells [37].”
Pruccoli, L., Breda, C., Teti, G., Falconi, M., Giorgini, F., & Tarozzi, A. (2021) · Pharmaceuticals · doi:10.3390/ph14101044 · Cited by 12
“The neuroprotective effects f ere f rt er ex l re sing fruit flies expressing a mutant HT exon 1 fragment (HTT93Q) pan-neuronally via the elavGAL4 driver [20].”
BackgroundMethodInfluentialAlcalá‐Vida, R., Lotz, C., Brulé, B., Séguin, J., Decraene, C., Awada, A., Bombardier, A., Cosquer, B., de Vasconcelos, A. P., Brouillet, E., et al. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102363 · Cited by 17
Canadian Association of Neurosciences Review: Polyglutamine Expansion Neurodegenerative Diseases
Truant, R., Raymond, L. A., Xia, J., Pinchev, D., Burtnik, A., & Atwal, R. S. (2006) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710000514x · Cited by 18
Intracellular translocation of histone deacetylase 5 regulates neuronal cell apoptosis
Wei, J., Lu, Q., Li, W., & He, W. (2015) · Brain Research · doi:10.1016/j.brainres.2015.01.043 · Cited by 15
“neurodegeneration in a variety of cell culture and in vivomodels (Langley et al., 2005; Steffan et al., 2001).”
BackgroundInfluentialShiraishi, R., Tamura, T., Sone, M., & Okazawa, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116567 · Cited by 15
“Effect of butyrate on viability and lifespan of the fly models We also tested the therapeutic effect of butyrate, since butyrate was reported to have a therapeutic effect on eye degeneration in an HD fly model [9].”
MethodHuntington’s Disease Pathogenesis: Mechanisms and Pathways
Spada, A. R. L., Weydt, P., & Pineda, V. V. (2011) · Europe PMC (PubMed Central) · Cited by 14
Bajracharya, R., & Ballard, J. W. O. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.10.003 · Cited by 14
Pharmacological intervention of early neuropathy in neurodegenerative diseases
Kwon, M. J., Kim, J., Kim, T. S., & Lee, S. B. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.003 · Cited by 14
High-Throughput and High-Content Screening for Huntington's Disease Therapeutics
Varma, H., Lo, D. C., & Stockwell, B. R. (2010) · Frontiers in neuroscience · doi:10.1201/ebk0849390005-c5 · Cited by 14
Activation of p38MAPK Contributes to Expanded Polyglutamine-Induced Cytotoxicity
Tsirigotis, M., Baldwin, R. M., Tang, M. Y. H., Lorimer, I. A. J., & Gray, D. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002130 · Cited by 13
Purification of Transcripts and Metabolites from Drosophila Heads
Jensen, K., Sanchez-Garcia, J., Williams, C. M., Khare, S., Mathur, K., Graze, R. M., Hahn, D. A., McIntyre, L. M., Rincón-Limas, D. E., & Fernández-Fúnez, P. (2013) · Journal of Visualized Experiments · doi:10.3791/50245 · Cited by 16
Delayed spinocerebellar ataxia in transgenic mice expressing mutant ubiquitin
Tsirigotis, M., Tang, M., Beyers, M., Zhang, M., Woulfe, J., & Gray, D. A. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00694.x · Cited by 14
Willyard, C. (2010) · Nature Medicine · doi:10.1038/nm0110-18 · Cited by 13
Hoshino, M., Tagawa, K., Okuda, T., & Okazawa, H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.086 · Cited by 13
Tallaksen‐Greene, S. J., Ordway, J. M., Crouse, A. B., Jackson, W. S., Detloff, P. J., & Albin, R. L. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10855 · Cited by 16
“…1994; Boutell et al., 1999; Lin et al., 2000; Luthi-Carter et al., 2000; McCampbell et al., 2000, 2001; Holbert et al., 2001; Nucifora et al., 2001; Steffan et al., 2000, 2001; Chai et al., 2001, 2002; Zhang et al., 2002; Dunah et al., 2002; Katsuno et al., 2002; Takeyama et al., 2002; Kegel et…”
Epigenetics in rare neurological diseases
Roberts, C.-T., Arezoumand, K. S., Shahib, A. K., Davie, J., & Rastegar, M. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1413248 · Cited by 20
“These insights provide a better understanding of the distinct regulatory effects of mHtt on CBP and p300 (Steffan et al., 2001; Jiang et al., 2006; Giralt et al., 2012).”
BackgroundSaadh, M. J., Ahmed, H. H., Kareem, R. A., Sanghvi, G. V., Ganesan, S., Agarwal, M., Kaur, P., Taher, W. M., Alwan, M., Jawad, M. J., et al. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.173972 · Cited by 12
Overview of autosomal dominant ataxias
Subramony, S. H. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-51892-7.00024-3 · Cited by 12
Epigenetics of cell fate reprogramming and its implications for neurological disorders modelling
Grzybek, M., Golonko, A., Walczak, M., & Lisowski, P. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.11.007 · Cited by 14
Ross, C. A., Kronenbuerger, M., Duan, W., & Margolis, R. L. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-801893-4.00002-x · Cited by 17
Decoding the role of coiled-coil motifs in human prion-like proteins
Behbahanipour, M., García‐Pardo, J., & Ventura, S. (2021) · Prion · doi:10.1080/19336896.2021.1961569 · Cited by 12
Polyglutamine disorders: Pathogenesis and potential drug interventions
Tandon, S., Aggarwal, P., & Sarkar, S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122562 · Cited by 15
Class II HDACs and Neuronal Regeneration
Tang, B. L. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24802 · Cited by 15
“HDAC inhibitors have indeed been shown to attenuate poly-glutamine extension-containing huntingtin-induced neurorodegeneration in Drosophila models of Huntington’s disease (HD) [Steffan et al., 2001].”
BackgroundPotential therapeutic targets in polyglutamine-mediated diseases
Katsuno, M., Watanabe, H., Yamamoto, M., & Sobue, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.956727 · Cited by 12
“Also, the abnormal interaction between soluble polyglutamine-expanded proteins and transcriptional co-activators is demonstrated in animal models of polyglutamine diseases as well as in the postmortem tissues of patients [24].”
BackgroundRepeat Expansion Disease Models
Ueyama, M., & Nagai, Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0529-0_5 · Cited by 13
CREB-Dependent Transcription and Synaptic Plasticity
Barco, Á., Jančić, D., & Kandel, E. R. (2007) · Springer eBooks · doi:10.1007/978-0-387-73609-9_7 · Cited by 14
Therapeutic Strategies for Huntington’s Disease
Mrzljak, L., & Muñoz-Sanjuán, I. (2013) · Current topics in behavioral neurosciences · doi:10.1007/7854_2013_250 · Cited by 13
“(Hockly et al. 2003; Jia et al. 2012a, b; McFarland et al. 2012; Mielcarek et al. 2011; Quinti et al. 2010; Sadri-Vakili et al. 2007; Steffan et al. 2001; Thomas et al. 2008).”
BackgroundDeutsch, S. I., Mastropaolo, J. P., Burket, J. A., & Rosse, R. B. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.12.011 · Cited by 13
Reynoso, M. A. R., Ochoa-Hernández, A. B., Juárez-Vázquez, C. I., & Barros‐Núñez, P. (2014) · Neurología · doi:10.1016/j.nrl.2014.02.004 · Cited by 13
Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases
Fan, H., Chi, C.-S., Cheng, S.-N., Lee, H.-F., Tsai, J., Lin, S., & Harn, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010026 · Cited by 12
“Levels of hypo-acetylation of histone were associated with down-regulated genes in HD, and HDACI revitalized the hypo-acetylation and improved the motor signs/symptoms of HD [122,124–127].”
BackgroundEpigenetic profiles in polyglutamine disorders
Liu, H., Tang, T.-S., & Guo, C. (2017) · Epigenomics · doi:10.2217/epi-2017-0089 · Cited by 13
Solana‐Manrique, C., Moltó, M. D., Calap-Quintana, P., Sanz, F., Llorens, J. V., & Paricio, N. (2019) · Springer eBooks · doi:10.1007/978-981-13-2218-1_15 · Cited by 16
Grote, S. K., & Spada, A. R. L. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072851 · Cited by 15
“In Drosophila, amino-terminal huntingtin fragments containing an expanded glutamine tract and the adjacent polyproline region were shown to directly interact with the acetyltransferase domain of two transcription factor co-activators, CBP and p/CAF (Steffan et al., 2001).”
BackgroundNew drugs for Huntington’s disease
Rosser, A., & Dunnett, S. B. (2002) · Neuroreport · doi:10.1097/00001756-200202110-00001 · Cited by 12
Histone deacetylase inhibitors
Price, S., & Dyke, H. J. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.7.745 · Cited by 12
“A role for the use of HDAC inhibitors in the treatment of Huntington’s chorea has been suggested previously [31,32] and recently reviewed [33] .”
BackgroundEnokido, Y., Maruoka, H., Hatanaka, H., Kanazawa, I., & Okazawa, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00477-1 · Cited by 12
Huntington's disease: The mystery unfolds?
Petersén, Å., & Brundin, P. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53012-9 · Cited by 13
Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Brett, A., Rosenstock, T. R., & Rego, A. C. (2014) · Current Drug Targets · doi:10.2174/1389450114666131124140704 · Cited by 13
“Important initial studies on the effect of HDAC inhibitors, namely suberoylanilide hydroxamic acid (SAHA) and sodium butyrate (SB), showed reduce lethality in Drosophila models of polyQ diseases [70].”
BackgroundNarayan, P. J., Reid, S. J., Scotter, E. L., McGregor, A. L., Mehrabi, N. F., Singh‐Bains, M. K., Glass, M., Faull, R. L. M., Snell, R. G., & Dragunow, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105092 · Cited by 13
Varshney, V., Kumar, A., Parashar, V., Kumar, A., Goyal, A., & Garabadu, D. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010277933231122111244 · Cited by 15
Gassman, A., Hao, L. T., Bhoite, L. T., Bradford, C. L., Chien, C.-B., Beattie, C. E., & Manfredi, J. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074325 · Cited by 12
Martí, E., & Estivill, X. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00045 · Cited by 13
Tandon, S., & Sarkar, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119358 · Cited by 12
Henry, R. A., Singh, T., Kuo, Y., Biester, A., O’Keefe, A. J., Lee, S., Andrews, A. J., & O’Reilly, A. M. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01070 · Cited by 10
Voicu, V. A., Tătaru, C. P., Toader, C., Covache-Busuioc, R.-A., Glavan, L.-A., Bratu, B.-G., Costin, H. P., Corlatescu, A.-D., & Ciurea, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613006 · Cited by 13
“Restoring this equilibrium through a genetic or pharmacological adjustment in histone deacetylases (HDACs) potentially offers therapeutic strategies using HDAC inhibitors against neurodegeneration [34].”
BackgroundModeling Huntington’s disease: An insight on in-vitro and in-vivo models
Rana, N., Kapil, L., Singh, C., & Singh, A. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114757 · Cited by 15
Pandian, G. N., Taylor, R. D., Syed, J., Saha, A., Chandran, A., Vaijayanthi, T., & Sugiyama, H. (2014) · Biomaterials Science · doi:10.1039/c4bm00068d · Cited by 10
Calamini, B., Lo, D. C., & Kaltenbach, L. S. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0195-4 · Cited by 9
Fluorescent molecular probe-based activity and inhibition monitoring of histone deacetylases
Roopa, Priya, B., Bhalla, V., Kumar, M., & Kumar, N. (2021) · Chemical Communications · doi:10.1039/d1cc04034k · Cited by 10
Spinobulbar muscular atrophy (Kennedy's disease)
Gallo, J. (2004) · Handbook of clinical neurophysiology · doi:10.1016/s1567-4231(04)04023-7 · Cited by 10
Liao, J., Morin, L. W., & Ahmad, S. T. (2014) · Journal of Visualized Experiments · doi:10.3791/51625 · Cited by 11
Lin, Y., He, H., Luo, Y., Zhu, T., & Duan, R. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9506-8 · Cited by 10
Bonfils, C., Walkinshaw, D. R., Besterman, J. M., Yang, X., & Li, Z. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.9.1041 · Cited by 10
Specific inhibition of Huntington's disease gene expression by siRNAs in cultured cells.
Liu, W., Goto, J., Wang, Y., Murata, M., Wada, K., & Kanazawa, I. (2003) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.79b.293 · Cited by 10
Huntington’s disease: A decade beyond gene discovery
Hogarth, P. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0003-3 · Cited by 20
An expanded role for wild-type huntingtin in neuronal transcription
Thompson, L. M. (2003) · Nature Genetics · doi:10.1038/ng0903-13 · Cited by 11
Self-citationCytoprotective effect of novel histone deacetylase inhibitors against polyglutamine toxicity
Kariya, S., Hirano, M., Uesato, S., Nagai, Y., Nagaoka, Y., Furiya, Y., Asai, H., Fujikake, N., Toda, T., & Ueno, S. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.09.019 · Cited by 10
Invertebrate models of neurologic disease: Insights into pathogenesis and therapy
Thompson, L. M., & Marsh, J. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0028-7 · Cited by 12
“For example, recent results show that SAHA (an HDAC inhibitor) and cystamine and Congo red (aggregation inhibitors) reduce pathology in a fly model of HD [ 42 ,50].”
ResultSelf-citationThe Bicyclic Depsipeptide Family of Histone Deacetylase Inhibitors
Townsend, P. A., Crabb, S. J., Davidson, S. M., Johnson, P., Packham, G., & Ganesan, A. (2007) · Chemical biology · doi:10.1002/9783527619375.ch12 · Cited by 10
Cano-Cano, F., Martín-Loro, F., Gallardo-Orihuela, A., González-Montelongo, M. D. C., Ortuño‐Miquel, S., Hervás-Corpión, I., de la Villa, P., Ramón-Marco, L., Navarro-Calvo, J., Gómez-Jaramillo, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54347-8 · Cited by 9
“…to analyse HD-linked neuroinflammation, allowing for the use of ex vivo retina cultures from HD mouse models to elucidate mechanisms of neurodegeneration and to evaluate potential therapeutic approaches 78 , as research models that are evolutionarily closer than HD Drosophila ommatidia 79–82 .”
Chen, Z. S., Peng, S. I., Leong, L. I., Gall-Duncan, T., Wong, N., Li, T. H., Lin, X., Wei, Y., Koon, A. C., Huang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58618-4 · Cited by 12
“Fly lines GMR-GAL4 87 , UAS-DsRed CAG0/100 3 , UAS-Htt exon1 Q93 28 , UAS-CTG 60/480 88 and UAS-CGG 90 -EGFP 89 were described previously.”
InfluentialMai, H. A., Thomas, C. M., Nge, G. G., & Elefant, F. (2025) · Cells · doi:10.3390/cells14120873 · Cited by 11
“Such reduced histone acetylation in HD patients, mouse, and Drosophila HD models causes chromatin hypoacetylation with concomitant transcriptional dysregulation of multiple genes, including those in involved in long-term memory [89,90].”
Therapeutic Potential of Sodium Butyrate in Neurological and Psychiatric Disorders
Rahmani, D., Chodari, L., Kakallahpour, M., & Niknam, Z. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05428-w · Cited by 16
Qiu, S., Xiao, C., & Robertson, R. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163976 · Cited by 9
The Lysine Demethylase KDM7A Regulates Immediate Early Genes in Neurons
Wang, Y., Hong, Q., Xia, Y., Zhang, Z., & Wen, B. (2023) · Advanced Science · doi:10.1002/advs.202301367 · Cited by 12
Genetic approaches in Drosophila for the study neurodevelopmental disorders
Okray, Z., & Hassan, B. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.09.007 · Cited by 12
“…as a valuable platform for neuropharmacological research and has been successfully used to identify therapeutic approaches to several brain disorders such as Huntington's and Fragile X Syndrome (Nichols, 2006; Steffan et al., 2001; McBride et al., 2005; Choi et al., 2010; Manev et al., 2003).”
Unraveling the Basis of Neurodegeneration using the Drosophila Eye
Fernández-Fúnez, P., Sanchez-Garcia, J., & Rincón-Limas, D. E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8232-1_10 · Cited by 10
Krench, M., Cho, R. W., & Littleton, J. T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw166 · Cited by 10
Raj, K., & Akundi, R. S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02314-z · Cited by 11
Acetylation State of Lysine 14 of Histone H3.3 Affects Mutant Huntingtin Induced Pathogenesis
Faragó, A., Zsindely, N., Farkas, A., Neller, A., Siági, F., Szabó, M. R., Csont, T., & Bodai, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315173 · Cited by 10
“Several studies have indicated that the Htt protein binds to the HATs CREB-binding protein (CBP/KAT3A) and P300/CBP-associated factor (PCAF/KAT2B), and that the interaction of these enzymes with mHtt leads to the inhibition of their catalytic activity and/or their degradation [18,19,30].”
BackgroundSelf-citationPhysiopathologie de la maladie de Huntington : état des connaissances
Roze, E. F., Bétuing, S., Deyts, C., Vidailhet, M., & Caboche, J. (2008) · Revue Neurologique · doi:10.1016/j.neurol.2008.03.006 · Cited by 11
Reynoso, M. A. R., Ochoa-Hernández, A. B., Juárez-Vázquez, C. I., & Barros‐Núñez, P. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.02.011 · Cited by 10
Jiang, Y., Berg, M. D., Genereaux, J. L., Ahmed, K., Duennwald, M. L., Brandl, C. J., & Lajoie, P. (2019) · Traffic · doi:10.1111/tra.12637 · Cited by 11
“closely associated with HD and histone deacetylase inhibitors improve the HD phenotype in animal models.(27,28,30,31,94,95) Thus, further analy-”
Background
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.